Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Morepen Labs adds three new drugs - Rivaroxaban, Vildagliptin and UDCA to its API portfolio

Posted On: 2019-10-14 09:40:58

Morepen Laboratories Ltd. has developed and added three blockbuster drugs to its portfolio of Active Pharmaceutical Ingredients (APIs) for sale in domestic and global markets. The three bulk drugs I APis are Rivaroxa ban (trade name Xarelto), Vildagliptin (trade names - Galvus, Zomelis) and UDCA (Ursodeoxycholic Acid). While two products Rivaroxaban and Yildagliptin will augment Morepen's presence in the Cardiac and Diabetic segments respectively, the third product UDCA will cater to the Liver segment.

The current global market size for Rivaroxaban, a powerful anticoagulant (blood thinner), is $7.1 9 Billion (Rs. 51,000 cores) and that of Vildagliptin, which is a strong oral Anti-diabetic drug used for the treatment of type 2 diabetes, is $1.28 Billion (Rs. 9,000 cores). The global market size for Rivaroxaban is likely to touch $9.00 Billion(Rs. 64,000 crore) by year 2023 and that of Yildagliptin $1.35 Billion (Rs. 9,600 crore) by 2021. Morepen Labs will initially target patent free markets for these two drugs globally. The Drug Master File (DMF) for regulatory markets like US etc will be filed within the next 12 months' time frame.

This was disclosed by Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd., here on Monday. "The company has already built-up additional capacities and is now all set to commercially launch these three new API's under its portfolio. Dedicated efforts of Morepen's in-house R&D Centre at Baddi (Himachal Pradesh), which was recently approved by Department of Scientific & Industrial Research, Govt. of India, has led to the release of these three products," he said.

"With a focus on new molecules, new patented processes, we now look forward towards investing more in our R&D Infrastructure for future growth of the company," Mr. Suri further pointed out.

Rivaroxaban is the 10th largest selling drug worldwide. It caters to the Cardiac market. It was initially developed and patented worldwide by Bayer. Morepen already has substantial presence in this category with two leading statins - Atorvastatin and Rosuvastatin that are aggressively being used for lowering cholesterol. Now with the addition of Rivaroxaban in Morepen's portfolio, company gets an added advantage in the cardiac market. The Indian patent for the drug is going to expire in Dec' 2019 which opens floodgates for the company to export the drug to all the patent free markets worldwide and also supply the product to the large domestic market where it is commonly used to prevent blood clots and used for cardiovascular symptoms such as angina, heart failure, rheumatic heart disease etc.

Vildagliptin caters to the Diabetics market worldwide. Morepen footprint in diabetic sector is well established with a series of "glilptins" like Sitagliptin, Linaglitptin, Saxagliptin and new series of"gliflozins" like Empagliflozin and Dapagliflozin, already developed by Morepen's R&D Centre. Development of low cost Vildagliptin, which is used for the treatment of metabolic disorders such as obesity, diabetes, PCOD & fatty liver etc., is a nice addition to growing Diabetic portfolio of the company. Vildagliptin patent is presently held by Novartis and this is set to expire worldwide in December 2019. Vildagliptin has about 25 per cent share of the Indian "gliptins" market of Rs. 3500 crore. Vildagliptin is the first molecule in the most commonly prescribed "gliptins" series that is going off patent and is certainly going to get good traction in the market.

UDCA is a niche product and has lot of technical challenges to synthesize. It is a naturally occurring product in the bile acid, found in normal human bile in small quantities. UDCA is used for the treatment of Primary Biliary Cirrhosis, a liver disease which occurs due to improper functioning of liver. It is also prescribed for the decrease in bile absorption, reduction in gallstone formation and also to relieve the symptoms of itching. UDCA has a niche market of $200million (Rs. 1,400 cores) and is expected to touch $300 million (Rs. 2,100 crore) by 2023. UDCA is already patent-free worldwide and ready for exporting across all the continents.

The bulk drugs (API) segment contributed marginally over 60 per cent to the company's total turnover in Q I FY 2019-20. API Exports grew by 50 percent during Q I and domestic API business grew by 33 per cent in the quarter. Morepen Labs has plans to invest in the areas of advance research related to new API molecules, patented technologies and new polymorphic form of the existing products. This will also give a big boost to the fresh R&D initiatives of the company for investing in future.

Shares of MOREPEN LABORATORIES LTD. was last trading in BSE at Rs.15.65 as compared to the previous close of Rs. 15.75. The total number of shares traded during the day was 50045 in over 127 trades.

The stock hit an intraday high of Rs. 16 and intraday low of 15.6. The net turnover during the day was Rs. 789933.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Aurobindo Pharma Ltd's Unit IV gets 14 observations from US FDA

Veto Switchgears and Cables reports Q2 FY20 results

Vedanta's Aluminium & Power Business wins Jamkhani Coal Block

Oracle Financial Services Software Reports Q2 Fiscal Year 2020

UFlex Closes Q2 of FY19-20 with EBITDA of 279 cr

Trigyn Technologies Ltd results - Highlights for Q2 & H1 FY2019-20

Fermenta Biotech Ltd board approves interim dividend of Rs. 5 for 2019-20

Pidilite Industries reports Q2 FY20 earnings

Navneet Education Limited Board approves interim dividend of Rs. for 2019-20

Singer India Limited announces Q2, H1 FY20 results

Saksoft Ltd H1FY20 Revenue at Rs. 178.39 Crs

New India Assurance Company Ltd reports Rs. 530 crores PAT in Q2

Ashoka Buildcon Q2FY20 EPC Revenue at Rs. 862Crores

Mishra Dhatu Nigam Ltd secures order of Rs. 106 crores

Nilkamal Ltd Board approves interim dividend of Rs. 5 for 2019-20

Snowman Logistics Ltd announces Q2 FY20 results

Mindteck Reports Financial Results for the Quarter Ended September 30, 2019

Cardinal Health Partners with TCS to Transform its IT Operating Model

SpiceJet posts a loss in Q2

ITD Cementation India Ltd Q2 consolidated net profit at Rs. 21.68 crores

Fine Organic Industries Ltd reports consolidated PAT of Rs. 57.03 crores in Q2

Hindustan Tin Works Ltd Q2 net profit jumps to Rs. 4.22 crores

Nandan Denim Ltd Q2 PAT at Rs. 2.20 crores

Amines & Plasticizers Ltd Q2 consolidated net profit soars to Rs. 6.85 crores

Galaxy Surfactants Ltd Q2 FY20 consolidated PAT climbs to Rs. 67.07 crores

Munjal Auto Industries Ltd reports consolidated net profit of Rs. 1.38 crore in Q2

A K Capital Services Ltd consolidated Q2 net profit at Rs. 10.47 crores

Trigyn Technologies Ltd posts consolidated PAT of Rs. 14.63 crores in Q2

Power Mech Projects Ltd Q2 FY20 consolidated net profit at Rs. 35.10 crores

SPL Industries Ltd Q2 net profit rises to Rs. 12.02 crores

Apex Frozen Foods Ltd Q2 net profit at Rs. 21.92 crores

KSE Ltd reports PAT of Rs. 4 crores in Q2

SEAMEC Ltd consolidated Q2 net profit at Rs. 26.82 crores

Nilkamal Ltd consolidated Q2 PAT at Rs. 49.01 crores

Gulshan Polyols Ltd reports net profit of Rs. 5.73 crores in Q2

Aarti Industries Ltd Q2 consolidated PAT at Rs. 147.56 crores

Permanent Magnets Ltd Q2 PAT higher at Rs. 3.71 crores

TD Power Systems Ltd reports consolidated PAT at Rs. 5.74 crores

CMI Ltd reports net profit of Rs. 1.09 crore in Q2

Cosmo Films Ltd Q2 consolidated PAT up at Rs. 28.70 crores

BATA India Ltd consolidated Q2 net profit at Rs. 71.30 crores

Finolex Cables Ltd posts consolidated PAT of Rs. 126.84 crores in Q2 FY20

Shreyans Industries Ltd reports net profit of Rs. 7.81 crores

Haryana Leather Chemicals Ltd posts PAT of Rs. 0.51 crore in Q2

Wanbury Ltd Q2 net profit at Rs. 5.02 crores

Saregama India Ltd consolidated Q2 net profit up at Rs. 19.26 crores

Himadri Speciality Chemical Ltd reports consolidated PAT at Rs. 45.16 crores

Thermax Ltd reports consolidated PAT declines to Rs. 25.70 crores

Lux Industries Ltd consolidated Q2 PAT at Rs. 40.59 crores

Indian Hume Pipe Company Ltd Q2 PAT slides to Rs. 14.20 crores







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019